The Federal Trade Commission on Friday initiated a legal process against middlemen that collectively administer about 80% of all prescriptions in the United States, accusing them of artificially inflating the list price of insulin drugs and blocking patients from accessing cheaper products. The FTC action targets the “Big Three” pharmacy benefit managers (PBMs): CVS Health’s Caremark Rx…
BROADCASTING FOR INDEPENDENCE
